Tyra Biosciences (TYRA) Interest Coverage Ratio (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Interest Coverage Ratio came in at 0.13 in Q1 2026, up 94.53% YoY from 0.07 in Q1 2025, and up 99.93% on a QoQ basis from 182.58 in Q4 2025.
Tyra Biosciences (TYRA) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Interest Coverage Ratio data on file, last reported at 0.13 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 94.53% year-over-year to 0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.44 (up 94.78% YoY) and the FY2025 annual result came in at 0.71, up 76.93% from the prior year.
- Interest Coverage Ratio advanced to 0.13 in Q1 2026, from 182.58 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 100.12 in Q4 2022 to a low of 182.58 in Q4 2025.
- A 5-year average of 12.72 and a median of 0.6 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio jumped 98.23% — and 2025, when it plunged 502.29%.
- Tracing TYRA's Interest Coverage Ratio over 5 years: stood at 100.12 in 2022, then tumbled by 100.6% to 0.6 in 2023, then sank by 16440.86% to 99.15 in 2024, then tumbled by 84.15% to 182.58 in 2025, then soared by 99.93% to 0.13 in 2026.
- The last three Interest Coverage Ratio figures came in at 0.13 (Q1 2026), 182.58 (Q4 2025), and 0.72 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.22 |
| Mar 31, 2026 | -0.13 |
| Dec 31, 2025 | -182.58 |
| Sep 30, 2025 | -0.72 |
| Jun 30, 2025 | -2.28 |
| Mar 31, 2025 | -2.37 |
| Dec 31, 2024 | -99.15 |
| Sep 30, 2024 | -0.26 |
| Jun 30, 2024 | -0.47 |
| Mar 31, 2024 | -0.39 |
| Sep 30, 2023 | -0.60 |
| Jun 30, 2023 | -0.28 |
| Mar 31, 2023 | -0.26 |
| Dec 31, 2022 | 100.12 |
| Sep 30, 2022 | -0.73 |
| Mar 31, 2022 | -0.74 |
| Dec 31, 2021 | 54.87 |
| Sep 30, 2021 | -0.17 |
| Jun 30, 2021 | -55.08 |
| Mar 31, 2021 | -42.11 |